The use of the World Health Organisation Anatomical Therapeutic Chemical/Defined Daily Dose methodology in Canada

Drug Information Journal

Volumn 38, Issue 1, 2004, Pages 15-27

  Sketris, Ingrid S ^a,b,c   Metge, Colleen J ^d   Ross, Jennifer L ^b   MacCara, Mary E ^b,e   Comeau, Donna G ^b   Kephart, George C ^b,f   Blackburn, Jim L ^g  

^a Coll of Pharm/Hlth Serv Admin ^*  (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c CHSRF/CIHR Chair in Hlth Serv Res   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e Biopharmaceutics and Drug Delivery Lab   (Canada)

^f Community Health and Epidemiology ^*  (Canada)

^g UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Anatomical Therapeutic Chemical Defined Daily Dose; Drug consumption studies; Drug utilization measurement

Indexed keywords

ALTEPLASE; AMOXICILLIN; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA LACTAM ANTIBIOTIC; CIMETIDINE; FIBRINOLYTIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PENICILLIN DERIVATIVE; PRAVASTATIN; PROTON PUMP INHIBITOR; SIMVASTATIN; STREPTOKINASE;

CANADA; DATA BASE; DRUG CLASSIFICATION; DRUG COST; DRUG UTILIZATION; HUMAN; PRIORITY JOURNAL; REVIEW; UTILIZATION REVIEW; WORLD HEALTH ORGANIZATION;

EID: 2942733135     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150403800104     Document Type: Review

References (35)

1. Tognoni G. Drug use and monitoring. In: Holland WW, ed. Evaluation of Health Care. London: Oxford University Press; 1983:207.
2. Canadian Institute for Health Information. Development of drug utilization indicators: A feasibility study using existing aggregated administrative databases. Ottawa, Ontario: Canadian Institute for Health Information; 2002.
3. Strom BL, ed. Pharmacoepidemiology. 2nd edition. Chichester, England: John Wiley & Sons Ltd; 1994.
4. Wertheimer AI. The defined daily dose system (DDD) for drug utilization review. Hosp Pharm. 1986;21(3):239-241,258.
5. World Health Organisation Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. 1st edition. Oslo, Norway: World Health Organisation; 1996.
6. World Health Organisation Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. 5th edition. Oslo, Norway: World Health Organisation; 2002.
7. World Health Organisation Collaborating Centre for Drug Statistics Methodology. ATC Index with DDDs. Oslo, Norway: World Health Organisation; 2002.
8. World Health Organisation Collaborating Centre for Drug Statistics Methodology, Oslo Norway. http://www.whocc.no/atcddd/. Accessed April 21, 2003.
9. World Health Organisation Collaborating Centre for International Drug Monitoring. The Uppsala Monitoring Centre, http://www.who-umc.org/umc.html. Accessed April 23, 2005.
10. Busto U, Lanctot KL, Isaac P, Adrian M. Benzodiazepine use and abuse in Canada. Can Med Assoc J. 1989;141(9):917-921.
11. Ruiz I, Offermanns J, Lanctot KL, Busto U. Comparative study on benzodiazepine use in Canada and Chile. J Clin Pharmacol. 1995;55(2):124-129.
12. Sketris IS, Kephart GC, Hicks VA, Hubbard EJ, Brown MG, Chandler RF, MacLean DR. Prescribing patterns of antilipemic drugs and prevalence of hypercholesterolemia in the Nova Scotia population more than 65 years old. Ann Pharmacother. 1995 Jun;29(6):576-581.
13. Anderson GM, Carter JA. Patterns of use of specific drugs in the elderly: Antidepressants, antibiotics and drugs to be avoided in the elderly. In Goel V, Williams JI, Anderson GM, Blackstein-Hirsch P, Fooks C, Naylor CD (eds). Patterns of Health Care in Ontario. The ICES Practice Atlas. 2nd ed. Ottawa, Canada: Canadian Medical Association; 1996: 323-328. Available at www.ices.on.ca/webbuild/ site/ices-internet-uploadfile_connection/Practice2- ch12.pdf. Accessed November 17, 2003.
14. Metge C, Black C, Peterson S, Kozyrskyj AL. The population's use of pharmaceuticals. Med Care. 1999;37(6):JS42-JS59.
15. Sketris I, Metge C, Blackburn J, Comeau D, Kephart G, MacCara M, Somers E, Shevchuk Y, Laturnas A. Anti-infective agent utilization of seniors in Nova Scotia, Saskatchewan and Manitoba, Canada 1995/96, 1996/97 and 1997/98 using the defined daily dose [abstract]. Pharmacoepidemiol Drug Safety. 2002; 11(1):91.
16. Wolf HK, Andreou P, Bata IR, Comeau DG, Gregor RD, Kephart G, MacLean DR, Sketris I. Trends in the prevalence and treatment of hypertension in Halifax County from 1985 to 1995. Can Med Assoc J. 1999;161(6):699-670.
17. Hutchinson JM. Reduction in Antibiotic Consumption in Hospital-Success of a Clinical Pharmacy Approach in St. John's [abstract]. Presented at the Canadian Association for Clinical Microbiology and Infectious Diseases, Nov 4-7, 2000. Ottawa, Canada.
18. Grootendorst PV, Dolovich LR, O'Brien BJ, Holbrook AM, Levy AR. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. Can Med Assoc J. 2001; 165(8): 1011-1019. Available at: http://collection.nlc- bnc. ca/100/201/500/cdn_medical_association/cmaj/ vol-165/issue-8/1011.asp. Accessed April 21, 2003.
19. Egan MY, Wolfson C, Moride Y, Monette J. High daily doses of benzodiazepines among Quebec seniors: prevalence and correlates. BioMedCentral Geriatr. 2001;1(1):4. Available at: http://www. biomedcentral.com/1471-2518/1/4. Accessed April 21, 2003.
20. Ayles J, Breau D, Hutchinson J. The use of the World Health Organisation (WHO) Defined Daily Dose (DDD) to compare antibiotic consumption through regional prescribing profiles [abstract]. Pharmacoepidemiol Drug Safety 2002: 11(1):95.
21. Marshall JK, Grootendorst, O'Brien BJ, Dolovich LR, Holbrook AM, Levy AR. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. Can Med Assoc J. 2002;166(13):1655-1662.
22. Sommers R, Kephart G, Sketris IS. Evaluation of Thrombolytic Drug Utilization and Expenditures in Nova Scotia Hospitals using the World Health Organization's Defined Daily Dose (DDD) Methodology[abstract]. Presented at the Canadian Health Economics Research Association Conference, May 22-25, 2002. Halifax, Nova Scotia.
23. Nordic Council on Medicines. Nordic Statistics on Medicines 1993-1995. Stockholm, Sweden: Norstedts tryckeri AB; 1996.
24. Hekster YA, Vree TB, Goris RJ, Boerema JB. The defined daily dose per 100 bed-days as a unit of comparison and a parameter for studying antimicrobial drug use in a university hospital. A retrospective study of the effects of guidelines and audit on antimicrobial drug use. J Clin Hosp Pharm. 1982;7:251-260.
25. Stolker JJ, Heerdink ER, Pullen SEJ, Santman FW, Yechiel AH, Leufkens HGM, Zitman FG. Determinants of psychotropic drug usage in a general intensive care unit. Gen Hosp Psychiatry. 1998;20: 371-376.
26. Kiivet RA, Dahl ML, Llerena A, Maimets M, Wettermark B, Berecz R. Antibiotic use in 3 European university hospitals. Scand J Infect Dis. 1998;30: 277-280.
27. Strom BL, ed. Pharmacoepidemiology. 3rd edition. Chichester, England: John Wiley & Sons Ltd; 2000.
28. Clarke KW, Gray D. The defined daily dose as a tool in pharmacoeconomics. Pharmacoeconomics. 1995;7(4):280-283.
29. Sketris I, Metge C, Blackburn J, MacCara M, Comeau D, Kephart G, Ross J. A Canadian Guide for Drug Utilization Studies using Administrative Pharmacy Claims Data: Focus on the WHO ATC System and Defined Daily Dose. Halifax, Nova Scotia: Dalhousie University; 2001.
30. Ronning M, Salvesen Blix H, Tange Harbo B, Strom H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose-are drug utilization data comparable? Eur J Clin Pharmacol. 2000;56:723-727
31. Health Canada. Drug Product Database, 1999. Available at http://www.hosc.gc.ca/hpb-dgps/ therapeut/htmleng/dpd.html. Accessed April 21, 2003.
32. Health Canada Drug Product Database Web Query (active and discontinued drug products). http://www.hc-sc.gc.ca/hpb/drugs-dpd/. Accessed April 21, 2003.
33. Health Canada Therapeutic Products Directorate Index. Fact Sheets (Drug Identification Number) and Forms (Changes in manufacturer's name and/or product name). http://www.hc-sc.gc.ca/ hpb-dgps/therapeut/htmleng/index.html. Accessed April 21, 2003.
34. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001 Oct;26(5):331-342.
35. Simmons MS, Nides MA, Rand CS, Wise RA, Tashkin DP. Unpredictability of deception in compliance with physician-prescribed bronchodilator inhaler use in a clinical trial. Chest. 2000;118:290-295.